Gilead Sciences’ Acquisition Of Immunomedics

Goodwin Procter LLP advised Centerview Partners on the deal. Centerview Partners acted as financial advisor to Immunomedics, Inc. (NASDAQ: IMMU), on the definitive agreement pursuant to…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here